Cell Source Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $17.27 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Cell Source Inc had its IPO on under the ticker symbol CLCS.
The company operates in the Healthcare sector and Biotechnology industry. Cell Source Inc has a staff strength of 1 employees.
Shares of Cell Source Inc opened at $0.4 at the start of the last trading session i.e. 2023-03-21.
The stocks traded within a range of $0.4 - $0.4, and closed at $0.4.
This is a 0% increase from the previous day's closing price.
A total volume of 2,500 shares were traded at the close of the day’s session.
In the last one week, shares of Cell Source Inc have increased by +5.26%.
Cell Source Inc's Key Ratios
Cell Source Inc has a market cap of $17.27 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Cell Source Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Cell Source Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cell Source Inc’s operating margin was 0% while its return on assets stood at -377.61% with a return of equity of 0%.
In Q3, Cell Source Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Cell Source Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.14 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cell Source Inc’s profitability.
Cell Source Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -14.9628. Its price to sales ratio in the trailing 12-months stood at 0.
Cell Source Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- Total Liabilities
- $6.74 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Cell Source Inc ended 2023 with $276809.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $276809.00 while shareholder equity stood at $-9997117.00.
Cell Source Inc ended 2023 with $0 in deferred long-term liabilities, $6.74 million in other current liabilities, 34437.00 in common stock, $-32471003.00 in retained earnings and $0 in goodwill. Its cash balance stood at $2597.00 and cash and short-term investments were $2597.00. The company’s total short-term debt was $6,273,993 while long-term debt stood at $0.
Cell Source Inc’s total current assets stands at $2597.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $332859.00 and inventory worth $0.
In 2023, Cell Source Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Cell Source Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Cell Source Inc stock is currently trading at $0.4 per share. It touched a 52-week high of $1.5 and a 52-week low of $1.5. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.43 and 200-day moving average was $0.37 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 3213.9% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Cell Source Inc
Similar Industry Stocks (Biotechnology)
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company’s lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.